Eli Lilly (LLY) closed the most recent trading day at $771.75, moving -3.45% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%.
Shares of the drugmaker witnessed a loss of 1.02% over the previous month, beating the performance of the Medical sector with its loss of 1.56%, and underperforming the S&P 500's gain of 4.97%.
The upcoming earnings release of Eli Lilly will be of great interest to investors. The company's earnings report is expected on August 7, 2025. The company is forecasted to report an EPS of $5.3, showcasing a 35.2% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.47 billion, up 28.06% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $21.88 per share and a revenue of $59.9 billion, indicating changes of +68.44% and +32.98%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.33% decrease. At present, Eli Lilly boasts a Zacks Rank of #4 (Sell).
In terms of valuation, Eli Lilly is presently being traded at a Forward P/E ratio of 36.54. This signifies a premium in comparison to the average Forward P/E of 13.77 for its industry.
We can additionally observe that LLY currently boasts a PEG ratio of 1.16. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.27 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 72, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
